Piper Jaffray Starts Adamas Pharmaceuticals (ADMS) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
Go back to Piper Jaffray Starts Adamas Pharmaceuticals (ADMS) at Overweight
May 5, 2014 7:31 AM EDT
William Blair initiated coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with an Outperform rating and a price target of $35.00.
For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.
Shares of Adamas Pharmaceuticals closed at $20.01 yesterday.
...
More
May 5, 2014 7:31 AM EDT
Credit Suisse initiated coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with an Outperform rating and a price target of $26.00.
For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.
Shares of Adamas Pharmaceuticals closed at $20.01 yesterday.
...
More
May 5, 2014 6:21 AM EDT
Needham & Company initiates coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with a Buy rating and a price target of $33.00.
Analyst Elliot Wilbur comments, "We are initiating coverage of Adamas Pharmaceuticals, a specialty pharma play with a validated platform for developing and commercializing pharmacokinetically enhanced... More
